[{"id":"a2663035-0db5-4a1d-8164-60f1d9f3d378","acronym":"","url":"https://clinicaltrials.gov/study/NCT01105169","created_at":"2021-01-18T04:22:27.086Z","updated_at":"2024-07-02T16:35:44.570Z","phase":"","brief_title":"Precision-Based Magnesium Trial","source_id_and_acronym":"NCT01105169","lead_sponsor":"Vanderbilt University Medical Center","biomarkers":" CRP • MT-CO2","pipe":" | ","alterations":" PTGS2 expression","tags":["CRP • MT-CO2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-06-28"},{"id":"8123b2d2-deaa-462c-ba64-a6b226fc5dcf","acronym":"IMpALA","url":"https://clinicaltrials.gov/study/NCT04188119","created_at":"2021-01-18T20:24:53.381Z","updated_at":"2024-07-02T16:35:47.784Z","phase":"Phase 2","brief_title":"A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04188119 - IMpALA","lead_sponsor":"The Christie NHS Foundation Trust","biomarkers":" HER-2 • ER • PGR • PTGS2","pipe":" | ","alterations":" HER-2 negative • PTGS2 expression","tags":["HER-2 • ER • PGR • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • aspirin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2023-05-17"},{"id":"c1a1af83-90fc-451d-8fcd-427d757b2ead","acronym":"","url":"https://clinicaltrials.gov/study/NCT04930354","created_at":"2021-06-18T23:52:44.282Z","updated_at":"2024-07-02T16:35:55.340Z","phase":"Phase 1","brief_title":"ECP-1014 Treatment for Patients With Solid Tumor Cancers","source_id_and_acronym":"NCT04930354","lead_sponsor":"Euclises Pharmaceuticals, Inc.","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ECP-1014"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-02-16"},{"id":"9ea2a040-0f4c-412d-ae67-1316e86c8a06","acronym":"","url":"https://clinicaltrials.gov/study/NCT01647776","created_at":"2021-02-24T12:54:11.253Z","updated_at":"2024-07-02T16:36:34.914Z","phase":"","brief_title":"Screening and Risk Factors of Colon Neoplasia","source_id_and_acronym":"NCT01647776","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"],"overall_status":"Completed","enrollment":" Enrollment 3315","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 08/11/2015","primary_completion_date":" 08/11/2015","study_txt":" Completion: 08/11/2016","study_completion_date":" 08/11/2016","last_update_posted":"2021-02-09"},{"id":"f2ccb155-4831-4f65-afea-0623ec426e1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00299195","created_at":"2021-02-24T12:52:38.575Z","updated_at":"2024-07-02T16:36:38.469Z","phase":"","brief_title":"A Randomized Study of Sulindac in Oral Premalignant Lesions","source_id_and_acronym":"NCT00299195","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 02/23/2006","start_date":" 02/23/2006","primary_txt":" Primary completion: 01/06/2020","primary_completion_date":" 01/06/2020","study_txt":" Completion: 01/06/2020","study_completion_date":" 01/06/2020","last_update_posted":"2020-11-19"},{"id":"e94bc33f-4b68-4cea-9cad-25269ea1d5ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT00020878","created_at":"2021-02-11T09:52:26.698Z","updated_at":"2024-07-02T16:36:42.420Z","phase":"Phase 2","brief_title":"Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers","source_id_and_acronym":"NCT00020878","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 03/01/2001","start_date":" 03/01/2001","primary_txt":" Primary completion: 11/01/2002","primary_completion_date":" 11/01/2002","study_txt":" Completion: 05/01/2009","study_completion_date":" 05/01/2009","last_update_posted":"2020-08-03"},{"id":"74313848-6b6f-4543-9ddd-07a7c1b55596","acronym":"","url":"https://clinicaltrials.gov/study/NCT03185871","created_at":"2021-01-18T15:42:31.720Z","updated_at":"2024-07-02T16:36:53.683Z","phase":"Phase 2","brief_title":"Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses","source_id_and_acronym":"NCT03185871","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" PGR • CD163 • SDC1 • PTGS2 • VIM • CD68","pipe":" | ","alterations":" PGR positive • PTGS2 expression • SDC1 expression","tags":["PGR • CD163 • SDC1 • PTGS2 • VIM • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive • PTGS2 expression • SDC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 10/10/2018","primary_completion_date":" 10/10/2018","study_txt":" Completion: 10/10/2018","study_completion_date":" 10/10/2018","last_update_posted":"2019-11-15"},{"id":"8498b86c-2eff-434b-a67f-e0f9f3688490","acronym":"IMpALA","url":"https://clinicaltrials.gov/study/NCT03794596","created_at":"2021-01-18T18:45:48.955Z","updated_at":"2024-07-02T16:36:57.894Z","phase":"Phase 2","brief_title":"A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","source_id_and_acronym":"NCT03794596 - IMpALA","lead_sponsor":"The Christie NHS Foundation Trust","biomarkers":" HER-2 • ER • PGR • PTGS2","pipe":" | ","alterations":" HER-2 negative • PTGS2 expression","tags":["HER-2 • ER • PGR • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • aspirin"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 02/28/2021","primary_completion_date":" 02/28/2021","study_txt":" Completion: 02/28/2021","study_completion_date":" 02/28/2021","last_update_posted":"2019-07-22"},{"id":"e236cba8-19db-4ce9-a82b-89167143d80f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03900871","created_at":"2021-02-24T13:02:34.363Z","updated_at":"2024-07-02T16:37:01.002Z","phase":"Phase 1","brief_title":"Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma","source_id_and_acronym":"NCT03900871","lead_sponsor":"Hebei Medical University Fourth Hospital","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 04/10/2019","start_date":" 04/10/2019","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2019-04-03"},{"id":"7586ebcf-271b-450c-82e2-c36e999f4495","acronym":"","url":"https://clinicaltrials.gov/study/NCT01661764","created_at":"2021-01-18T07:10:40.723Z","updated_at":"2024-07-02T16:37:10.167Z","phase":"Phase 2","brief_title":"Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention","source_id_and_acronym":"NCT01661764","lead_sponsor":"Vanderbilt University","biomarkers":" PTGS2 • HPGD","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2 • HPGD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 02/04/2013","start_date":" 02/04/2013","primary_txt":" Primary completion: 12/26/2016","primary_completion_date":" 12/26/2016","study_txt":" Completion: 01/23/2018","study_completion_date":" 01/23/2018","last_update_posted":"2018-06-08"},{"id":"8ecb7624-1e34-46a2-8e81-e407b465fc51","acronym":"","url":"https://clinicaltrials.gov/study/NCT00052611","created_at":"2021-01-18T00:05:52.353Z","updated_at":"2024-07-02T16:37:12.672Z","phase":"Phase 2","brief_title":"Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia","source_id_and_acronym":"NCT00052611","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • AKT1 • BAX • PTGS2 • CD31 • PECAM1","pipe":" | ","alterations":" BCL2 expression • BAX expression • CD31 expression • PTGS2 expression • VEGFA expression","tags":["BCL2 • AKT1 • BAX • PTGS2 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • BAX expression • CD31 expression • PTGS2 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/01/2002","start_date":" 06/01/2002","primary_txt":" Primary completion: 03/01/2005","primary_completion_date":" 03/01/2005","study_txt":" Completion: 03/01/2005","study_completion_date":" 03/01/2005","last_update_posted":"2018-03-29"},{"id":"b0fd3737-b4f3-467c-9727-c9c2cb7b8306","acronym":"COMET","url":"https://clinicaltrials.gov/study/NCT02238821","created_at":"2021-01-18T10:30:15.962Z","updated_at":"2024-07-02T16:37:24.791Z","phase":"","brief_title":"Role of the MET Oncogene in Human Colorectal Cancer - A Translational Study","source_id_and_acronym":"NCT02238821 - COMET","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" MET • PTGS2","pipe":" | ","alterations":" MET expression • PTGS2 expression","tags":["MET • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression • PTGS2 expression"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2007","start_date":" 10/01/2007","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-03-03"}]